NCT02472548已完成1 期
A Phase I Randomized, Observer-blind, Controlled, Dose Escalation Trial of the Safety and Tolerability of Two Intramuscular Doses of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine Containing Respiratory Syncytial Virus (RSV) SHe Antigen and a Novel Adjuvant DepoVaxTM, or SHe A Antigen Co-administered With Aluminum Hydroxide, or Placebo to Healthy Adults ≥50-64 Years of Age
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- Number of participants with adverse events as a measure of safety and reactogenicity of the intramuscular DPX-RSV(A)
研究概览
简要总结
Administration of DPX-RSV(A), a Respiratory Syncytial Virus vaccine containing Respiratory Syncytial Virus (RSV) SHe antigen and DepoVaxTM adjuvant to healthy adults ≥50-64 years of age.
详细描述
This is a phase 1, First in Humans, randomized (2:2:1) observer blind, controlled, dose ranging, multi-arm parallel-group clinical trial in healthy persons 50 to 64 years of age to assess the safety and immunogenicity of two dose levels of a novel vaccine formulation DPX-RSV(A) consisting of a synthetic Respiratory Syncytial Virus SHe antigen combined with a novel adjuvant DepoVaxTM, compared to the antigen combined with the commonly used adjuvant Aluminum hydroxide, and to a saline placebo control.
The study will evaluate two different doses of DPX-RSV(A) and two doses of the RSV SHe antigen with aluminum hydroxide (RSV(A)-Alum), and a placebo control. The study is randomized, controlled, and observer-blinded in order that allocation to treatment is concealed from the investigative team and the participant. The inclusion of comparator groups (a placebo control group and the RSV(A)-Alum) allows for estimation of the attributable risk of adverse events. Since the study vaccines are not identical in appearance, an unblinded study nurse who has no other role in the study will administer the study vaccines.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 50 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 50-64 years, inclusive.
- •Good general health status, as determined by history and physical examination no greater than 30 days prior to administration of the test article.
- •Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of Diary Cards, return for follow-up visits).
- •Written informed consent obtained from the participant.
- •If female of child-bearing potential and heterosexually active, has practiced adequate contraception for 30 days prior to injection, has a negative pregnancy test on the day of injection, and has agreed to continue adequate contraception until 180 days after injection. (Please refer to the glossary for the definition of child-bearing potential and adequate contraception).
排除标准
- •Use of any investigational or non-registered product (drug or vaccine) other than the study product within 28 days preceding the dose of study product, or planned use during the study period.
- •Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device).
- •Planned administration/ administration of a vaccine/product not foreseen by the study protocol within the period starting 28 days before injection of a study vaccine and ending 84 days after.
- •Administration of immunoglobulins and/or any blood products within the 3 months preceding the dose of study product or planned administration during the study period.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. (Laboratory testing for HIV, Hepatitis C and Hepatitis B will be performed during the screening visit).
- •Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drug within 6 months prior to the product dose (for corticosteroids, this will mean prednisone ≥ 20 mg/day, or equivalent). Inhaled and topical steroids are allowed.
- •Family history of congenital or hereditary immunodeficiency.
- •History of or current autoimmune disease.
- •History of hypersensitivity to any test article constituent or products used during the course of study procedures.
- •Known or suspected hypersensitivity to any ingredient in the formulation or component of the container.
- •Pregnant or lactating female.
- •Female planning to become pregnant or planning to discontinue contraceptive precautions within 180 days of study vaccine receipt.
- •Any hematological (hemoglobin level, white blood cell [WBC], and platelet count) and biochemical (alanine aminotransferase [ALT], aspartate aminotransferase [AST], blood urea nitrogen [BUN] and creatinine) abnormality as per local laboratory normal values considered clinically significant by the investigator.
- •Transient mild laboratory abnormalities may be rescreened and the participant will be deemed eligible if the laboratory repeat test is normal as per local laboratory normal values and investigator assessment.
- •Any acute or chronic, clinically significant disease, as determined by physical examination or laboratory screening tests.
- •Malignancies within previous 5 years (excluding non-melanic skin cancer) and lymphoproliferative disorders.
- •Current alcoholism and/or drug abuse.
- •Acute disease and/or fever at the time of Screening ≥ 38°C
- •Fever is defined as temperature ≥ 38° /100.4°F by any route; the preferred route for recording temperature in this study will be oral.
- •Participants with a minor illness (such as mild diarrhea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator.
- •Participants with acute disease and/ or fever at the time of Screening may be re-screened at a later date.
- •Planned move to a location that will prohibit participating in the trial until study end.
- •Any other condition that the investigator judges may interfere with study procedures (e.g. drawing blood) or findings (e.g. immune response).
结局指标
主要结局
Number of participants with adverse events as a measure of safety and reactogenicity of the intramuscular DPX-RSV(A)
时间窗: Up to 28 Days after first injection.
次要结局
- The immunogenicity of the DPX-RSV(A) as measured by antibodies directed to the SHe antigen(28 days after one dose of vaccine and 28 days after a the second dose of a two-dose vaccine schedule as measured by antibodies directed to the SHe antigen.)
- Persistence of the humoral immune response to two doses of the RSV investigational vaccines, as measured by anti-SHe antibodies(From Day 28 to Day 180 after second vaccination)
- Number of participants with adverse events as a measure of safety of a second dose of the DPX-RSV(A)(180 days after vaccination.)
研究者
Joanne Langley
Principal Investigator
Dalhousie University
研究点 (2)
Loading locations...
相似试验
已完成
1 期
RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.Respiratory Syncytial Virus InfectionsNCT01805921ReiThera Srl72
已完成
不适用
Prospective Study in Respiratory Syncytial Virus Infected Japanese Adults, in Outpatient and Inpatient Settingsacute respiratory infectionJPRN-UMIN000019120Janssen Pharmaceutica NV100
已完成
1 期
Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy AdultsRespiratory Syncytial VirusNCT03049488National Institute of Allergy and Infectious Diseases (NIAID)95
已完成
1 期
A First in Human Study to Evaluate the Safety and Immune Response to a Vaccine for the Treatment of a Respiratory Virus, When Administered Into the Arm in Healthy Adult ParticipantsRespiratory Syncytial Virus InfectionsNCT04851977Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.60
已完成
1 期
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and ChildrenRespiratory Syncytial Virus InfectionsNCT01968083National Institute of Allergy and Infectious Diseases (NIAID)51